Cargando…

Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity

Background: Class IA phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) is an integral mediator of insulin signaling. The p110 catalytic and p85 regulatory subunits of PI3K are the products of separate genes, and while they come together to make the active heterodimer, they have opposing roles in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhari, Aditi, Ejeskär, Katarina, Wettergren, Yvonne, Kahn, C. Ronald, Rotter Sopasakis, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020741/
https://www.ncbi.nlm.nih.gov/pubmed/29983910
http://dx.doi.org/10.12688/f1000research.12418.2
_version_ 1783335357819912192
author Chaudhari, Aditi
Ejeskär, Katarina
Wettergren, Yvonne
Kahn, C. Ronald
Rotter Sopasakis, Victoria
author_facet Chaudhari, Aditi
Ejeskär, Katarina
Wettergren, Yvonne
Kahn, C. Ronald
Rotter Sopasakis, Victoria
author_sort Chaudhari, Aditi
collection PubMed
description Background: Class IA phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) is an integral mediator of insulin signaling. The p110 catalytic and p85 regulatory subunits of PI3K are the products of separate genes, and while they come together to make the active heterodimer, they have opposing roles in insulin signaling and action. Deletion of hepatic p110α results in an impaired insulin signal and severe insulin resistance, whereas deletion of hepatic p85α results in improved insulin sensitivity due to sustained levels of phosphatidylinositol (3,4,5)-trisphosphate. Here, we created mice with combined hepatic deletion of p110α and p85α (L-DKO) to study the impact on insulin signaling and whole body glucose homeostasis. Methods: Six-week old male flox control and L-DKO mice were studied over a period of 18 weeks, during which weight and glucose levels were monitored, and glucose tolerance tests, insulin tolerance test and pyruvate tolerance test were performed. Fasting insulin, insulin signaling mediators, PI3K activity and insulin receptor substrate (IRS)1-associated phosphatidylinositol kinase activity were examined at 10 weeks. Liver, muscle and white adipose tissue weight was recorded at 10 weeks and 25 weeks. Results: The L-DKO mice showed a blunted insulin signal downstream of PI3K, developed markedly impaired glucose tolerance, hyperinsulinemia and had decreased liver and adipose tissue weights. Surprisingly, however, these mice displayed normal hepatic glucose production, normal insulin tolerance, and intact IRS1-associated phosphatidylinositol kinase activity without compensatory upregulated signaling of other classes of PI3K. Conclusions: The data demonstrate an unexpectedly overall mild metabolic phenotype of the L-DKO mice, suggesting that lipid kinases other than PI3Ks might partially compensate for the loss of p110α/p85α by signaling through other nodes than Akt/Protein Kinase B.
format Online
Article
Text
id pubmed-6020741
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-60207412018-07-06 Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity Chaudhari, Aditi Ejeskär, Katarina Wettergren, Yvonne Kahn, C. Ronald Rotter Sopasakis, Victoria F1000Res Research Article Background: Class IA phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) is an integral mediator of insulin signaling. The p110 catalytic and p85 regulatory subunits of PI3K are the products of separate genes, and while they come together to make the active heterodimer, they have opposing roles in insulin signaling and action. Deletion of hepatic p110α results in an impaired insulin signal and severe insulin resistance, whereas deletion of hepatic p85α results in improved insulin sensitivity due to sustained levels of phosphatidylinositol (3,4,5)-trisphosphate. Here, we created mice with combined hepatic deletion of p110α and p85α (L-DKO) to study the impact on insulin signaling and whole body glucose homeostasis. Methods: Six-week old male flox control and L-DKO mice were studied over a period of 18 weeks, during which weight and glucose levels were monitored, and glucose tolerance tests, insulin tolerance test and pyruvate tolerance test were performed. Fasting insulin, insulin signaling mediators, PI3K activity and insulin receptor substrate (IRS)1-associated phosphatidylinositol kinase activity were examined at 10 weeks. Liver, muscle and white adipose tissue weight was recorded at 10 weeks and 25 weeks. Results: The L-DKO mice showed a blunted insulin signal downstream of PI3K, developed markedly impaired glucose tolerance, hyperinsulinemia and had decreased liver and adipose tissue weights. Surprisingly, however, these mice displayed normal hepatic glucose production, normal insulin tolerance, and intact IRS1-associated phosphatidylinositol kinase activity without compensatory upregulated signaling of other classes of PI3K. Conclusions: The data demonstrate an unexpectedly overall mild metabolic phenotype of the L-DKO mice, suggesting that lipid kinases other than PI3Ks might partially compensate for the loss of p110α/p85α by signaling through other nodes than Akt/Protein Kinase B. F1000 Research Limited 2018-06-05 /pmc/articles/PMC6020741/ /pubmed/29983910 http://dx.doi.org/10.12688/f1000research.12418.2 Text en Copyright: © 2018 Chaudhari A et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chaudhari, Aditi
Ejeskär, Katarina
Wettergren, Yvonne
Kahn, C. Ronald
Rotter Sopasakis, Victoria
Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity
title Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity
title_full Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity
title_fullStr Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity
title_full_unstemmed Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity
title_short Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity
title_sort hepatic deletion of p110α and p85α results in insulin resistance despite sustained irs1-associated phosphatidylinositol kinase activity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020741/
https://www.ncbi.nlm.nih.gov/pubmed/29983910
http://dx.doi.org/10.12688/f1000research.12418.2
work_keys_str_mv AT chaudhariaditi hepaticdeletionofp110aandp85aresultsininsulinresistancedespitesustainedirs1associatedphosphatidylinositolkinaseactivity
AT ejeskarkatarina hepaticdeletionofp110aandp85aresultsininsulinresistancedespitesustainedirs1associatedphosphatidylinositolkinaseactivity
AT wettergrenyvonne hepaticdeletionofp110aandp85aresultsininsulinresistancedespitesustainedirs1associatedphosphatidylinositolkinaseactivity
AT kahncronald hepaticdeletionofp110aandp85aresultsininsulinresistancedespitesustainedirs1associatedphosphatidylinositolkinaseactivity
AT rottersopasakisvictoria hepaticdeletionofp110aandp85aresultsininsulinresistancedespitesustainedirs1associatedphosphatidylinositolkinaseactivity